CAL
VRCA icon

Capital Analysts LLC’s Verrica Pharmaceuticals VRCA Stock Holding History

Capital Analysts LLC’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9K Hold
1,500
– – ﹤0.01% 1318
2026
Q1 		$8K Hold
1,500
– – ﹤0.01% 1305
2025
Q4 		$12K Hold
1,500
– – ﹤0.01% 1219
2025
Q3 		$6K Sell
1,500
-630
-30% -$3.8K ﹤0.01% 1290
2025
Q2 		$11K Buy
2,130
+500
+31% +$2.69K ﹤0.01% 1134
2025
Q1 		$7K Buy
1,630
+300
+23% +$1.94K ﹤0.01% 1185
2024
Q4 		$9K Buy
1,330
+700
+111% +$7.69K ﹤0.01% 1085
2024
Q3 		$9K Buy
+630
New +$28.4K ﹤0.01% 1053

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Analysts LLC's VRCA Position: Q2 2026 in Review

Capital Analysts LLC held its Verrica Pharmaceuticals (VRCA) position steady in Q2 2026 at 1,500 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1318.

Capital Analysts LLC first reported a position in VRCA in Q3 2024 and has held it in 8 quarters since. The position peaked at $12K in Q4 2025. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

  • Capital Analysts LLC held 1,500 shares of Verrica Pharmaceuticals worth $9K as of Q2 2026.
  • Capital Analysts LLC left its Verrica Pharmaceuticals share count unchanged in Q2 2026.
  • Verrica Pharmaceuticals made up ﹤0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #1318 holding.
  • Capital Analysts LLC first reported a position in Verrica Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Capital Analysts LLC's Verrica Pharmaceuticals position peaked at $12K in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.